About this trial
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Eligibility criteria
Qualifiers
18 - 45 years.
Body mass index between 18.5-35.0 kg/m2
Not pregnant or expecting to become pregnant (females only)
Not postmenopausal (females only).
Disqualifiers
Not between the ages of 18-45
Body mass index < 18.5 kg/m2 or >35.0 kg/m2
Pregnant (females only)
Postmenopausal status (females only).
Trial design
Treatments tested in this trial
- High-Glycemic Breakfast Containing Cereal and Fresh Mango
- High-Glycemic Breakfast Containing Cereal and Table Sugar
Treatment groups
Sponsors and collaborators
Ball State University
Lead sponsor
National Mango Board
Collaborator